Traws Pharma, Inc.

For the period ended Mar 31, 2025. Filed May 15, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

TRAW$0.24+8.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Operations (unaudited)


· · Three Months Ended March 31, ·
· 2025 · 2024
Revenue	$57,000	$56,000
Operating expenses:
Research and development	2,506,000	1,912,000
General and administrative	2,754,000	3,356,000
Total operating expenses	5,260,000	5,268,000
Loss from operations	(5,203,000)	(5,212,000)
Change in fair value of warrant liability	26,513,000	—
Other income, net	180,000	229,000
Net income (loss)	$21,490,000	$(4,983,000)
Net income (loss) attributable to common stockholders, basic and diluted	$15,083,000	$(4,983,000)
Weighted-average shares of common stock outstanding, basic	6,965,927	841,738
Net income (loss) per share of common stock, basic	$2.17	$(5.92)
Weighted-average shares of common stock outstanding, diluted	7,215,125	841,738
Net income (loss) per share of common stock, diluted	$2.09	$(5.92)
Net income (loss) attributable to Series C Preferred stockholders, basic and diluted	$6,407,000	$—
Weighted-average shares of Series C Preferred outstanding, basic and diluted	7,398	—
Net income (loss) per share of Series C Preferred, basic and diluted	$866.04	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.